Customer Support: +44 (0)203 327 3140

Your region & currency

United Kingdom English(GB)

Pricing in GBP £

Local sites

  • Shopping Cart
    There are no items in your cart

We noticed you are browsing from United States. Switch to our United States site for local pricing in USD.

Dismiss alert

AAMI TIR48:2015(R2021)

Superseded

Superseded

View Superseded by

Quality Management System (QMS) Recommendations on the Application of the U.S. FDA’s CGMP Final Rule on Combination Products

Available format(s)

PDF

Language(s)

English

Published date

26-03-2021

Superseded date

02-05-2024

Superseded by

AAMI TIR48:2024

£127.30
Excluding VAT
Summarise this standard

This Technical Information Report (TIR) provides recommendations on the application of CGMPs for drugs, devices, biologics, and human cells, tissues, and cellular and tissue based products during development and marketing of combination products (drug-device, biologic-device, drug-biologic, or drug-device-biologic), in accordance with the FDA’s final rule (21 CFR Part 4; 78 FR 4307, 2013—hereafter "The Rule" or "FDA's Final Rule").

DocumentType
Technical Report
ISBN
978-1-57020-590-3
Pages
28
PublisherName
Association for the Advancement of Medical Instrumentation
Status
Superseded
SupersededBy
Supersedes

⚠

A newer version of this standard is available.

View Current Edition
£127.30
Excluding VAT